Edmond DE Rothschild Holding S.A. Buys New Holdings in Geron Corporation $GERN

Edmond DE Rothschild Holding S.A. purchased a new position in Geron Corporation (NASDAQ:GERN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,330,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,982,000. Edmond DE Rothschild Holding S.A. owned approximately 0.36% of Geron as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. RA Capital Management L.P. grew its position in Geron by 5.6% in the 4th quarter. RA Capital Management L.P. now owns 63,771,366 shares of the biopharmaceutical company’s stock valued at $84,178,000 after purchasing an additional 3,392,000 shares during the period. BlackRock Inc. bought a new position in shares of Geron in the second quarter valued at $62,868,000. Vanguard Group Inc. grew its holdings in shares of Geron by 3.6% during the fourth quarter. Vanguard Group Inc. now owns 35,660,969 shares of the biopharmaceutical company’s stock valued at $47,072,000 after buying an additional 1,237,844 shares during the last quarter. State Street Corp increased its position in shares of Geron by 0.9% during the fourth quarter. State Street Corp now owns 26,867,322 shares of the biopharmaceutical company’s stock worth $35,465,000 after acquiring an additional 248,508 shares in the last quarter. Finally, Vestal Point Capital LP raised its holdings in shares of Geron by 8.0% in the 2nd quarter. Vestal Point Capital LP now owns 23,775,000 shares of the biopharmaceutical company’s stock worth $33,523,000 after acquiring an additional 1,769,660 shares during the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Stock Down 2.5%

Shares of NASDAQ GERN opened at $1.55 on Friday. The company has a current ratio of 6.91, a quick ratio of 5.16 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average of $1.41 and a 200-day moving average of $1.48. The firm has a market capitalization of $995.83 million, a price-to-earnings ratio of -14.09 and a beta of 0.61. Geron Corporation has a 12 month low of $1.04 and a 12 month high of $2.01.

Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Geron had a negative net margin of 34.17% and a negative return on equity of 24.48%. The company had revenue of $57.48 million during the quarter, compared to analysts’ expectations of $55.30 million. Sell-side analysts expect that Geron Corporation will post -0.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $4.00.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.